About Xcovery

Our History & Mission

Founded in 2006 and headquartered in West Palm Beach, Florida, Xcovery is comprised of an experienced team that is dedicated to advancing next generation targeted therapeutics as promising new treatments to improve the lives of cancer patients. In January 2011, the company advanced Tyrogenex X-82, a novel VEGFR/PDGFR small molecule inhibitor, into Phase I clinical trials to explore the safety and tolerability of this drug candidate in patients with advanced solid tumors. Our mission is to create drugs with the ideal complement of efficacy and safety characteristics which can be used in combination therapy, the future of molecular targeted therapy in cancer.

Our Team

Xcovery’s CEO, Sheridan Snyder, is a veteran entrepreneur who began his biotech career in 1981 when he founded Genzyme, followed by Biotage, Upstate Biotechnology and now Xcovery and Tyrogenex. Mr. Snyder has funded Xcovery’s first 5 years of development, through his personal investment vehicle, BioCatalyst International, Inc. This is consistent with his “formula” for developing more than 14 start-ups over a 40 year period, all of which are operating successfully today.

Xcovery’s Chief Scientific Officer, Dr. Chris Liang, served as Director, Medicinal Chemistry at SUGEN (acquired by Pfizer in 2003) where he developed Sutent®, an FDA approved VEGFR/PDGFR angiogenesis inhibitor for the treatment of kidney cancer and second-line gastrointestinal cancer in Gleevec-resistant patients. The result of his knowledge, extensive experience and a unique set of medicinal chemistry design tools have enabled Xcovery to create a broad portfolio of kinase inhibitors.

Xcovery’s Vice President, Oncology, Dr. Jay Gibbons, brings more than 25 years of oncology research and management experience to the team with a strong emphasis on translational medicine. During his previous role as AVP, Oncology Research at Wyeth, he was instrumental in filing eight IND’s and the NDA for Torisel® (temsirolimus), currently approved for the treatment of renal cell carcinoma.

Virtual Model

We operate our business on a virtual basis with minimal infrastructure, contracting out most activities to key CROs, manufacturers, regulatory and clinical consultants. Xcovery also has several active collaborations with leading academic and clinical centers to further validate the use of our drug candidates in a number of disease indications and in various combinations.